platinum has been researched along with Neuroendocrine Tumors in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Albers, D; Kasper, S; Lahner, H; Markus, P; Mende, B; Mika, S; Reis, H; Rosery, V; Schmid, KW; Schuler, M; Schumacher, B; Siveke, JT; Stuschke, M; Treckmann, J; Wiesweg, M | 1 |
| Adamo, V; Cantale, O; Castorina, L; Chillari, F; Colarossi, C; Esposito, F; Franchina, T; Giuffrida, D; Puliafito, I; Ricciardi, GRR; Russo, A; Sciacca, D; Vitale, MP | 1 |
| Gu, X; Guan, Y; Hao, Y; Song, Z; Sun, Y; Wang, W; Xiang, J; Yao, Q; Zeng, X | 1 |
| Kojima, E; Kuba, H; Matsumura, M | 1 |
| Alonso-Gordoa, T; Brabander, T; Cadiot, G; Caminoa, A; Capdevila, J; Chakrabarty, B; Couvelard, A; Cros, J; de Mestier, L; García Gómez-Muriel, MI; Garcia-Alvarez, A; Hernando, J; Kats-Ugurlu, G; Lamarca, A; Landolfi, S; Manoharan, P; Pavel, ME; Perrier, M; Ronot, M; Van Velthuysen, MF; Walenkamp, AM; Zandee, W | 1 |
| Furukawa, M; Furuse, J; Hara, K; Hashigo, S; Hijioka, S; Hosoda, W; Ikeda, M; Imamura, M; Ishii, H; Ito, T; Kanno, A; Kawaguchi, Y; Kitano, M; Kobayashi, N; Kodama, Y; Komoto, I; Maguchi, H; Matayoshi, N; Matsuo, K; Mine, T; Miyabe, K; Mizuno, N; Morizane, C; Murohisa, G; Nakamori, S; Notohara, K; Okusaka, T; Taguchi, H; Takagi, T; Tanaka, H; Tsuchiya, Y; Tsuji, A; Ueno, M; Yanagimoto, H; Yane, K; Yatabe, Y; Yoshida, T; Yoshitomi, H | 1 |
| Armstrong, AJ; George, D; Gupta, RT; Harrison, M; Healy, P; Humeniuk, MS; McNamara, M; Ramalingam, S; Wu, Y; Zhang, T | 1 |
7 other study(ies) available for platinum and Neuroendocrine Tumors
| Article | Year |
|---|---|
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.
Topics: Etoposide; Gastrointestinal Neoplasms; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Prognosis; Retrospective Studies; Stomach Neoplasms | 2023 |
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Topics: Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Lung; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neuroendocrine Tumors; Platinum; Retrospective Studies | 2023 |
[Responsiveness of well-differentiated PanNET G3 to platinum-based chemotherapy: a case report].
Topics: Antineoplastic Agents; Humans; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum | 2019 |
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
Topics: Adenocarcinoma; Etoposide; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Retrospective Studies; Somatostatin; Treatment Outcome | 2021 |
Rb Loss and
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Female; Humans; Japan; Male; Middle Aged; Mutation; Neoplasm Grading; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Platinum; Prognosis; Proto-Oncogene Proteins p21(ras); Retinoblastoma Protein; Survival Analysis | 2017 |
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Topics: Adenocarcinoma; Aged; Disease Progression; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Platinum; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |